Home

GW is the global leader in developing cannabinoid-based medicines. From our experience in multiple sclerosis treatment, GW is now also developing products to treat rare and catastrophic forms of childhood-onset epilepsy.

GW’s vision is to be the global leader in prescription cannabinoid medicines, developing and commercializing pharmaceutical products which address clear unmet needs.
Justin Gover, Chief Executive Officer

Recent News

Jul 22, 2018
London, UK, 23 July 2018: GW Pharmaceuticals plc (Nasdaq: GWPH, “GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, will announce on 7 August, 2018 its third quarter financial results for the period ending 30 June, 2018. GW will also host a conference call the same day at 4:30 p.m. EDT. Conference call information will be provided in the financial results press release. A…
Jun 24, 2018
- Approval for seizures associated with Lennox-Gastaut Syndrome or Dravet Syndrome, two rare, severe childhood-onset epilepsies - London, UK, Carlsbad, CA, June 25, 2018: GW Pharmaceuticals plc (Nasdaq: GWPH, “GW,” “the Company” or “the Group”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, along with its U.S. subsidiary Greenwich Biosciences, announced today that the U.S. Food and Drug…
Jun 06, 2018
London, UK, Carlsbad, CA, 6 June, 2018: GW Pharmaceuticals plc (NASDAQ: GWPH, GW, the Company or the Group), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced that GW management will present at the Goldman Sachs 39th Annual Global Healthcare Conference on Wednesday, June 13, 2018 at 10:00 a.m. PT at the Terranea Resort, in Rancho Palos Verde, CA . A live audio webcast of the…